<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114296</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000430701</org_study_id>
    <secondary_id>CSMC-00006359</secondary_id>
    <secondary_id>CSMC-00000509</secondary_id>
    <nct_id>NCT00114296</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer</brief_title>
  <official_title>A Pilot Study to Evaluate the Effects of Omega-3 Fatty Acids on Intermediate Markers of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs or supplements to keep cancer from&#xD;
      forming, growing, or coming back. The use of omega-3 fatty acids may prevent breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying how well omega-3 fatty acids work in&#xD;
      preventing breast cancer in women at high risk of developing breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the effects of omega-3 fatty acids on mammographic breast density (MBD) in&#xD;
           women at high risk of developing breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine, preliminarily, the effects of this supplement on cell atypia and breast cell&#xD;
           proliferation measured in ductal lavage specimens from these patients.&#xD;
&#xD;
        -  Determine the effects of this supplement on circulating hormone and growth factor blood&#xD;
           levels in these patients.&#xD;
&#xD;
        -  Determine the effects of this supplement on the expression of estrogen-related proteins&#xD;
           found in ductal lavage specimens from these patients.&#xD;
&#xD;
        -  Determine the effects of this supplement on plasma lipid peroxidation levels in these&#xD;
           patients.&#xD;
&#xD;
        -  Correlate the modifying effect of lipid peroxidation-related genes with MBD in patients&#xD;
           treated with this supplement.&#xD;
&#xD;
      OUTLINE: This is a randomized, pilot study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral placebo three times daily for 12 months.&#xD;
&#xD;
        -  Arm II: Patients receive oral omega-3 fatty acids three times daily for 12 months.&#xD;
&#xD;
      In both arms, treatment continues in the absence of the development of ductal carcinoma in&#xD;
      situ or invasive carcinoma of the breast or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients (40 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2005</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Breast density as measured by the Madena method at 1 year</measure>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega-3 fatty acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  At increased risk of developing breast cancer, as defined by 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  5-year Gail risk ≥ 1.7%&#xD;
&#xD;
               -  Calculated 5-year Gail risk ≥ 5 times the average for age group, as defined by 1&#xD;
                  of the following:&#xD;
&#xD;
                    -  At least 0.1% (for patients age 20-29)&#xD;
&#xD;
                    -  At least 1.0% (for patients age 30-39)&#xD;
&#xD;
                    -  At least 1.7% (for patients age 40 and over)&#xD;
&#xD;
               -  Known BRCA1 or BRCA2 mutation carrier&#xD;
&#xD;
               -  Family history consistent with hereditary breast cancer, as defined by any of the&#xD;
                  following:&#xD;
&#xD;
                    -  At least 4 relatives diagnosed with breast cancer at any age&#xD;
&#xD;
                    -  At least 2 first-degree relatives diagnosed with breast cancer at age 50 or&#xD;
                       younger&#xD;
&#xD;
                    -  Breast and ovarian cancer diagnosed in the same relative&#xD;
&#xD;
                    -  At least 2 occurrences of breast cancer and 1 occurrence of ovarian cancer&#xD;
                       at any age in the same family&#xD;
&#xD;
               -  Atypical hyperplasia or lobular carcinoma in situ of the breast by prior biopsy&#xD;
&#xD;
               -  History of unilateral ductal carcinoma in situ of the breast&#xD;
&#xD;
               -  History of invasive stage I breast cancer in remission (completed local and&#xD;
                  systemic standard therapy)&#xD;
&#xD;
               -  History of ovarian cancer in remission for &gt; 5 years&#xD;
&#xD;
          -  Baseline mammogram performed within the past 6 months with an interpretation of not&#xD;
             suspicious for malignancy (BIRAD 1-3)&#xD;
&#xD;
          -  Not eligible for OR refused standard breast cancer risk reduction strategies (e.g.,&#xD;
             prophylactic oophorectomy, prophylactic mastectomy, or tamoxifen)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  SWOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT and/or SGPT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No underlying medical, psychiatric, or social condition that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 6 months since prior and no concurrent hormonal therapy, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Antiestrogens&#xD;
&#xD;
               -  Estrogen&#xD;
&#xD;
               -  Selective estrogen-receptor modulators&#xD;
&#xD;
               -  Progestins&#xD;
&#xD;
               -  Aromatase inhibitors&#xD;
&#xD;
               -  Hormonal contraceptives&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior bilateral mastectomy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 months since prior and no concurrent chronic (i.e., &gt; 3 times per week)&#xD;
             non-steroidal anti-inflammatory drugs (e.g., aspirin, ibuprofen, or indomethacin) or&#xD;
             cyclooxygenase-2 inhibitors&#xD;
&#xD;
          -  No prior cancer treatment that would preclude study treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agustin Garcia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2006</verification_date>
  <study_first_submitted>June 13, 2005</study_first_submitted>
  <study_first_submitted_qc>June 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2005</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

